Ewing's sarcoma natural history: Difference between revisions
Jump to navigation
Jump to search
m Robot: Changing Category:Disease state to Category:Disease |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Ewing's sarcoma}} | {{Ewing's sarcoma}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
{{CMG}}; '''Assistant Editor(s)-In-Chief:''' [[User:Michael Maddaleni|Michael Maddaleni, B.S.]] | {{CMG}}; '''Assistant Editor(s)-In-Chief:''' [[User:Michael Maddaleni|Michael Maddaleni, B.S.]] | ||
| Line 7: | Line 11: | ||
==Prognosis== | ==Prognosis== | ||
Out of all primary [[musculoskeletal]] [[tumors]], Ewing's Sarcoma has maintained the form with the most unfavorable long term prognosis.<ref name="pmid17272319">{{cite journal |author=Iwamoto Y |title=Diagnosis and treatment of Ewing's sarcoma |journal=[[Japanese Journal of Clinical Oncology]] |volume=37 |issue=2 |pages=79–89 |year=2007 |month=February |pmid=17272319 |doi=10.1093/jjco/hyl142 |url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17272319 |accessdate=2011-12-09}}</ref> In fact, prior to multi-drug [[chemotherapy]], the survival rate was less than 10%. Now that there have been many options developed, such as chemotherapy, surgery, and irradiation, long term survival has increased to greater than 50% in most clinical centers.<ref name="pmid17272319">{{cite journal |author=Iwamoto Y |title=Diagnosis and treatment of Ewing's sarcoma |journal=[[Japanese Journal of Clinical Oncology]] |volume=37 |issue=2 |pages=79–89 |year=2007 |month=February |pmid=17272319 |doi=10.1093/jjco/hyl142 |url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17272319 |accessdate=2011-12-09}}</ref> | * Out of all primary [[musculoskeletal]] [[tumors]], Ewing's Sarcoma has maintained the form with the most unfavorable long term prognosis.<ref name="pmid17272319">{{cite journal |author=Iwamoto Y |title=Diagnosis and treatment of Ewing's sarcoma |journal=[[Japanese Journal of Clinical Oncology]] |volume=37 |issue=2 |pages=79–89 |year=2007 |month=February |pmid=17272319 |doi=10.1093/jjco/hyl142 |url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17272319 |accessdate=2011-12-09}}</ref> In fact, prior to multi-drug [[chemotherapy]], the survival rate was less than 10%. Now that there have been many options developed, such as chemotherapy, surgery, and irradiation, long term survival has increased to greater than 50% in most clinical centers.<ref name="pmid17272319">{{cite journal |author=Iwamoto Y |title=Diagnosis and treatment of Ewing's sarcoma |journal=[[Japanese Journal of Clinical Oncology]] |volume=37 |issue=2 |pages=79–89 |year=2007 |month=February |pmid=17272319 |doi=10.1093/jjco/hyl142 |url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17272319 |accessdate=2011-12-09}}</ref> | ||
Staging attempts to distinguish patients with localized from those with [[metastasis|metastatic]] disease. Most commonly, [[metastasis|metastases]] occur in the chest, bone and/or bone marrow. Less common sites include the [[central nervous system]] and [[lymph node]]s. | * Staging attempts to distinguish patients with localized from those with [[metastasis|metastatic]] disease. Most commonly, [[metastasis|metastases]] occur in the chest, bone and/or bone marrow. Less common sites include the [[central nervous system]] and [[lymph node]]s. | ||
* Survival for localized disease is 65-70% when treated with [[chemotherapy]]. Long term survival for [[metastasis|metastatic]] disease can be less than 10% but some sources state it is 25-30%. | |||
Survival for localized disease is 65-70% when treated with [[chemotherapy]]. Long term survival for [[metastasis|metastatic]] disease can be less than 10% but some sources state it is 25-30%. | |||
==Complications== | ==Complications== | ||
* The treatments needed to fight this disease have many complications, which should be discussed on an individual basis. | |||
==References== | ==References== | ||
| Line 24: | Line 28: | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Needs content]] | |||
Revision as of 19:15, 7 September 2012
|
Ewing's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ewing's sarcoma natural history On the Web |
|
American Roentgen Ray Society Images of Ewing's sarcoma natural history |
|
Risk calculators and risk factors for Ewing's sarcoma natural history |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor(s)-In-Chief: Michael Maddaleni, B.S.
Overview
Natural History
Prognosis
- Out of all primary musculoskeletal tumors, Ewing's Sarcoma has maintained the form with the most unfavorable long term prognosis.[1] In fact, prior to multi-drug chemotherapy, the survival rate was less than 10%. Now that there have been many options developed, such as chemotherapy, surgery, and irradiation, long term survival has increased to greater than 50% in most clinical centers.[1]
- Staging attempts to distinguish patients with localized from those with metastatic disease. Most commonly, metastases occur in the chest, bone and/or bone marrow. Less common sites include the central nervous system and lymph nodes.
- Survival for localized disease is 65-70% when treated with chemotherapy. Long term survival for metastatic disease can be less than 10% but some sources state it is 25-30%.
Complications
- The treatments needed to fight this disease have many complications, which should be discussed on an individual basis.
References
- ↑ 1.0 1.1 Iwamoto Y (2007). "Diagnosis and treatment of Ewing's sarcoma". Japanese Journal of Clinical Oncology. 37 (2): 79–89. doi:10.1093/jjco/hyl142. PMID 17272319. Retrieved 2011-12-09. Unknown parameter
|month=ignored (help)